Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of intravenously administered fosfomycin in treating severely infected patients across Europe. This prospective, multicenter, non-interventional study focuses on infections such as osteomyelitis, complicated urinary tract infections, nosocomial lower respiratory tract infections, bacterial meningitis or central nervous system infections, bacteraemia or sepsis, skin and soft tissue infections, endocarditis, and other infections covered by national guidelines. Patients receive fosfomycin intravenously according to the respective national Summary of Product Characteristics SmPC. The study is observational and does not involve randomization or placebo. It includes monitoring during treatment and follow-up periods, with evaluations up to six months for treatment outcomes and up to one year for osteomyelitis follow-up. The study documents clinical and microbiological cure rates, clinical improvements, and sodium and potassium serum levels during hospital stays. Participants are assessed for clinical success at multiple points, including initial response within 7 days, end of treatment up to 6 months, test of cure, and follow-up up to one year for osteomyelitis. Safety monitoring includes daily recording of adverse events, serious adverse events, adverse drug reactions, and deaths during treatment and follow-up. The study tracks dropouts due to treatment failure or adverse events. Overall, participation duration varies depending on treatment and follow-up schedules.
Actively Recruiting
This clinical trial studies seladelpar, a drug being evaluated for its effects on people with primary biliary cholangitis PBC who have compensated cirrhosis. The main goal is to compare seladelpar with a placebo to see how it impacts event-free survival EFS, which measures the time until certain liver-related events occur over a period of up to 156 weeks. This research is led by Gilead Sciences and takes place in a phase 3 setting, aiming to better understand treatment outcomes for PBC patients with cirrhosis. Participants with Child-Pugh class A cirrhosis will receive 10 mg of seladelpar orally once daily, while those with Child-Pugh class B will receive 5 mg once daily, both for up to 36 months. Another group with either Child-Pugh class A or B will receive a placebo matching the study drug daily for the same duration. After 156 weeks, participants with Child-Pugh class A or B who remain on the study drug may continue seladelpar at the respective doses for an additional maximum of 3 years during an open-label extension phase. Participants will be monitored throughout the study with regular assessments to evaluate liver function and clinical events related to PBC and cirrhosis. Researchers will measure outcomes such as event-free survival, overall survival, time to hospitalization, and liver transplant-free survival. Safety and liver health will be closely followed using laboratory tests and imaging. The total participation time may extend up to several years, depending on continued study drug use and follow-up requirements.
Actively Recruiting
Researchers are conducting a phase III trial to evaluate the safety and effectiveness of autologous skeletal muscle-derived cells for patients with urge fecal incontinence caused by dysfunction or damage to the external anal sphincter. This study aims to assess clinical outcomes in patients who have not sufficiently improved with conservative treatments. The condition involves uncontrolled leakage due to sphincter weakness or disruption. Participants receive either injections of their own skeletal muscle-derived cells into the external anal sphincter or a placebo solution. The study is randomized with two groups one receiving the investigational cell therapy and the other receiving the placebo vehicle. Both treatments are administered under medical supervision, and the study follows participants over a 12-month period to assess changes in incontinence episodes. During the trial, participants will be monitored for safety and efficacy through regular evaluations. The main outcome measured is the change in the frequency of incontinence episodes over 12 months. The study includes thorough assessments such as anal manometry and ultrasound imaging of the anal canal. Participants adherence, symptoms, and safety are carefully tracked through scheduled visits throughout the trial duration.